Plenary Session 3
Monday, September 11, 11:30–13:00

Session Title
Radiotheranostics: What’s new?

Chairpersons
Ken Herrmann (Essen, Germany)
Cristina Nanni (Bologna, Italy)

Programme

11:30 – 11:33 Introduction by Chairperson

11:33 – 11:47 Jonathan Strosberg (Tampa, USA): PRRT in Neuroendocrine Tumours as a Paradigm for Progress in Radiopharmaceuticals: Where are we and where will we be?

11:47 – 12:02 Michael Hofman (Melbourne, AUS): 2023: PSMA state of the art

12:02 - 12:16 Sandra Heskamp (Nijmegen, The Netherlands): PSMA.2.0

12:16 – 12:30 Andreas Buck (Würzburg, Germany): CXCR4: Ready for Prime Time!

12:30 – 12:44 Katharina Lückerath (Essen, Germany): Targeting the tumour microenvironment: next breakthrough?!?

12:44 – 12:57 Lena Unterrainer (Munich, Germany / Los Angeles, USA): Dark Horses of Theranostics

12:57 – 13:00 Summary by Chairperson

Educational Objectives
1. Extend knowledge regarding theranostics
2. Expand understanding of new developments in approved indications such as NET and mCRPC
3. Understand current state of development new non-approved concepts and indications

Summary
Theranostics remains one if not the most exciting topic in Nuclear Medicine. This plenary session gathers world leading experts providing overviews of the current state of approved and non-approved theranostic concepts. Moreover, the speakers will dare outlooks into the short and long term future outlining of theranostics helping us to understand what will be areas of growth while also highlighting challenges and opportunities. Do not miss this line up of world class theranostic pioneers!

Key Words
Theranostics – PSMA – PRRT – CXCR4 – cMET – new radioligands